Results 81 to 90 of about 281,370 (287)

A targeted immunotherapy approach for HER2/neu transformed tumors by coupling an engineered effector domain with interferon-γ

OncoImmunology, 2018
Despite substantial clinical progress with targeted therapies, current antibody-based approaches have limited efficacy at controlling HER2/neu-positive breast cancers, especially in the absence of chemotherapies.
Hongtao Zhang, Lian Lam, Yasuhiro Nagai, Zhiqiang Zhu, Xi Chen, Mei Q. Ji, Mark I. Greene   +6 more
doaj   +1 more source

Epirubicin With Cyclophosphamide Followed by Docetaxel With Trastuzumab and Bevacizumab as Neoadjuvant Therapy for HER2-Positive Locally Advanced Breast Cancer or as Adjuvant Therapy for HER2-Positive Pathologic Stage III Breast Cancer: A Phase II Trial of the NSABP Foundation Research Group, FB-5 [PDF]

, 2017
Background The purpose of this study was to determine the cardiac safety and clinical activity of trastuzumab and bevacizumab with docetaxel after epirubicin with cyclophosphamide (EC) in patients with HER2-positive locally advanced breast cancer (LABC ...
Ansari, Bilal, Buyse, Marc E., Conlin, Alison K., Geyer, Charles E., Jr., Gross, Howard M., Jacobs, Samuel A., Keogh, George P., Lord, Raymond S., Mamounas, Eleftherios P., Mauquoi, Celine, Patocskai, Erica J., Polikoff, Jonathan A., Rastogi, Priya, Robidoux, André, Smith, John W., Stella, Philip J., Swain, Sandra M., Wolmark, Norman   +17 more
core   +2 more sources

Blood‐based proteomic profiling reveals context‐dependent changes in BCL2‐associated signaling during taxane therapy in breast cancer patients

FEBS Open Bio, EarlyView.
Chemotherapy side effects significantly impact cancer survivors' quality of life. Using protein levels in blood samples from breast cancer patients before and after 12 weeks of taxane treatment, we detected treatment‐dependent changes in calcium signaling and aging pathways associated with cancer recurrence.
Saira Munshani, Eiman Y. Ibrahim, Rozalyn L. Rodwin, Leah M. Ferrucci, Kim Blenman, Maryam Lustberg, Barbara E. Ehrlich   +6 more
wiley   +1 more source

Customizing the therapeutic response of signaling networks to promote antitumor responses by drug combinations [PDF]

, 2014
Drug resistance, de novo and acquired, pervades cellular signaling networks (SNs) from one signaling motif to another as a result of cancer progression and/or drug intervention.
Bown, James L., Goltsov, Alexey, Goltsov, Gregory, Harrison, David J., Langdon, Simon P.   +4 more
core   +5 more sources

Common Signatures of Altered Gene Regulation and Invasiveness of Different Breast Cancer Cell Lines after Matrix Interface Crossing

Advanced Healthcare Materials, EarlyView.
Interface transmigration reprograms triple‐negative breast cancer cells, triggering a shared switch toward more aggressive and invasive phenotypes. Using a collagen I interface model, this study identifies shared transcriptional changes involving proliferation, chromatin remodeling, and DNA repair pathways.
Cornelia Clemens, Hannah Trampert, Nataliia Kotsiuba, Tilo Pompe   +3 more
wiley   +1 more source

Deciphering the Role of Cancer Stem Cells in Breast Cancer Brain Colonization Using a Novel Patient‐Derived Model

Advanced Healthcare Materials, EarlyView.
This study shows that stem‐like cells isolated from breast cancer brain metastases drive the spread and growth of tumors in the brain. Among them, a highly adhesive subgroup initiates metastasis and resists many drugs. By closely reflecting patient tumors, these models help identify new targets and improve the development of effective treatments ...
Stefania Faletti, Cristina Richichi, Daniela Osti, Elena Ceccacci, Giovanni Bertalot, Camilla Cerutti, Giuseppina Giardina, Adriana Marinaro, Brunella Costanza, Valentina Gambino, Elena Zaccheroni, Daniela Tosoni, Maria G. Filippone, Marcello Del Corvo, Yinxiu Zhan, Teresa Gravina, Davide Corà, Monica Patanè, Bianca Pollo, Maria Giovanna Jodice, Salvatore Pece, Babette B. Weksler, Ignacio A. Romero, Pierre‐Olivier Couraud, Elisabetta Munzone, Massimiliano Del Bene, Francesco DiMeco, Giuliana Pelicci   +27 more
wiley   +1 more source

KRAS, NRAS, BRAF, HER2 and microsatellite instability in metastatic colorectal cancer – practical implications for the clinician

Radiology and Oncology, 2019
Colorectal cancer is a successful model of genetic biomarker development in oncology. Currently, several predictive or prognostic genetic alterations have been identified and are used in clinical practice.
Afrăsânie Vlad-Adrian, Marinca Mihai Vasile, Alexa-Stratulat Teodora, Gafton Bogdan, Păduraru Marius, Adavidoaiei Anca Maria, Miron Lucian, Rusu Cristina   +7 more
doaj   +1 more source

Plant‐Produced Viral Nanoparticles Decorated with Nanobodies Against HER2 Improve Retention and Recruitment of Immune Cells in Solid Tumors

Advanced Healthcare Materials, EarlyView.
Potato virus X is a filamentous RNA plant virus that can be engineered into a molecular tool for cancer therapy. We produced genetically‐encoded virus‐derived nanoparticles decorated with nanobodies targeting cancer cell receptors, epidermal growth factor receptor (EGFR) and human epidermal growth factor 2 (HER2).
Enrique Lozano‐Sanchez, Miguel A. Moreno‐Gonzalez, Fernando Merwaiss, Nicole F. Steinmetz, José‐Antonio Daròs   +4 more
wiley   +1 more source

The Combined Effect of Nanobubble-IR783-HPPH-Affibody Complex and Laser on HER2-Positive Breast Cancer

International Journal of Nanomedicine, 2023
Wenbin Cai,1,2,* Wei Lv,1,3,* Li Meng,2 Yunyou Duan,1 Li Zhang1 1Department of Ultrasound Medical, Tangdu Hospital, the Fourth Military Medical University, Xi’an, People’s Republic of China; 2Department of Ultrasound Diagnostics, General Hospital
Cai W, Lv W, Meng L, Duan Y, Zhang L
doaj  

Structure–Activity Relationship of HER2 Receptor Targeting Peptide and Its Derivatives in Targeted Tumor Therapy

Biomolecules, 2020
Human epidermal growth factor (HER2) is a transmembrane tyrosine kinase receptor that is frequently overexpressed in breast cancer. Its increased level prognoses a poor patient outcome and a high mortality rate. Despite the widening spectrum of therapies
Beáta Biri-Kovács, Afrodité Adorján, Ildikó Szabó, Bálint Szeder, Szilvia Bősze, Gábor Mező   +5 more
doaj   +1 more source